Department of Human Pathology, A.O.U. Polyclinic G. Martino, Messina, Italy.
Anticancer Res. 2011 Apr;31(4):1315-20.
Hematopoietic progenitor cells (HPCs) are able to prepare the site for incoming neoplastic cells. Among different markers of HPCs, which one should be considered the most efficient was investigated.
Five hundred and seventy-nine non-metastatic lymph nodes from 49 patients affected by invasive breast cancer were submitted to an immunohistochemical comparative analysis of hematopoietic (CD34), endothelial (CD133), mesenchymal (CD117) progenitors and vascular endothelial growth factor receptor 1 (VEGFR1, also known as Flt1). The cases with an intensity-distribution score >3 were considered as high HPC expressors. Survival univariate and multivariate analyses were performed.
Fifteen out of the 49 patients were recorded as HPC high expressors based on the immunohistochemical VEGFR1 staining. A highly significant relationship was found between high HPC immunoexpression and the development of distant metastasis as well as the occurrence of bone localization (p<0.001). By univariate analysis, CD133 showed a highly significant value regarding metastatic localizations in the bone; by multivariate analysis, CD133 emerged as the only independent prognostic variable.
CD133 expression shows a potential predictive role, thus representing a helpful tool for the management of breast cancer.
造血祖细胞（HPC）能够为进入的肿瘤细胞做好准备。在 HPC 的不同标志物中，研究了哪一个最有效。
对 49 例浸润性乳腺癌患者的 579 个非转移性淋巴结进行了造血（CD34）、内皮（CD133）、间充质（CD117）祖细胞和血管内皮生长因子受体 1（VEGFR1，也称为 Flt1）的免疫组织化学比较分析。将强度分布评分>3 的病例视为高 HPC 表达者。进行了生存单因素和多因素分析。
根据免疫组织化学 VEGFR1 染色，49 例患者中有 15 例被记录为 HPC 高表达者。高 HPC 免疫表达与远处转移的发展以及骨定位的发生之间存在高度显著的关系（p<0.001）。单因素分析显示 CD133 与骨内转移性定位有显著相关性；多因素分析显示 CD133 是唯一独立的预后变量。
CD133 表达显示出潜在的预测作用，因此代表了乳腺癌管理的有用工具。
